Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

bryant ranch prepack - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e), dihydrocodeine bitartrate (unii: 8lxs95bsa9) (dihydrocodeine - unii:n9i9hdb855) - acetaminophen 320.5 mg - trezix™ (acetaminophen, caffeine, and dihydrocodeine bitartrate) capsules are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings], reserve trezix™ for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia trezix™ is contraindicated for: - all children younger than 12 years of age [see warnings and precautions] - post-operative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy [see warnings and precautions]. - trezix​tm ​ is also contraindicated in patients with: - significant respiratory depression [see warnings] - acute or severe bronchial asthma in an unmonitored setting

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - dihydrocodeine tartrate -

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - dihydrocodeine tartrate -

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - dihydrocodeine tartrate -

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - dihydrocodeine tartrate -

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - dihydrocodeine tartrate -

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - dihydrocodeine tartrate -

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

skylar laboratories, llc - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e), dihydrocodeine bitartrate (unii: 8lxs95bsa9) (dihydrocodeine - unii:n9i9hdb855) - dvorah is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings ], reserve dvorah for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] - have not been tolerated, or are not expected to be tolerated - have not provided adequate analgesia, or are not expected to provide adequate analgesia dvorah is contraindicated for: - all children younger than 12 years of age [see warnings and precautions ] - post-operative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy [see warnings and precautions ]. dvorah is also contraindicated in patients with: - significant respiratory depression [see warnings ] - acute or severe bronchial asthma in

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

galen limited - dihydrocodeine bitartrate - tablets - 30 milligram

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

ennogen healthcare international ltd - dihydrocodeine tartrate - modified-release tablet - 60mg